Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Receptor selectivity from minimal backbone modification of a polypeptide agonist.

Liu S, Cheloha RW, Watanabe T, Gardella TJ, Gellman SH.

Proc Natl Acad Sci U S A. 2018 Nov 15. pii: 201815294. doi: 10.1073/pnas.1815294115. [Epub ahead of print]

PMID:
30442659
2.

Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses.

Woodham AW, Cheloha RW, Ling J, Rashidian M, Kolifrath SC, Mesyngier M, Duarte JN, Bader JM, Skeate JG, Da Silva DM, Kast WM, Ploegh HL.

Cancer Immunol Res. 2018 Jul;6(7):870-880. doi: 10.1158/2326-6066.CIR-17-0661. Epub 2018 May 23.

PMID:
29792298
3.

Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with Broad β Residue Distribution.

Cheloha RW, Chen B, Kumar NN, Watanabe T, Thorne RG, Li L, Gardella TJ, Gellman SH.

J Med Chem. 2017 Nov 9;60(21):8816-8833. doi: 10.1021/acs.jmedchem.7b00876. Epub 2017 Oct 24.

4.

Rapid capture and labeling of cells on single domain antibodies-functionalized flow cell.

Chen GY, Li Z, Duarte JN, Esteban A, Cheloha RW, Theile CS, Fink GR, Ploegh HL.

Biosens Bioelectron. 2017 Mar 15;89(Pt 2):789-794. doi: 10.1016/j.bios.2016.10.015. Epub 2016 Oct 5.

5.

Backbone Modification of a Parathyroid Hormone Receptor-1 Antagonist/Inverse Agonist.

Cheloha RW, Watanabe T, Dean T, Gellman SH, Gardella TJ.

ACS Chem Biol. 2016 Oct 21;11(10):2752-2762. Epub 2016 Aug 17.

6.

PTH receptor-1 signalling-mechanistic insights and therapeutic prospects.

Cheloha RW, Gellman SH, Vilardaga JP, Gardella TJ.

Nat Rev Endocrinol. 2015 Dec;11(12):712-24. doi: 10.1038/nrendo.2015.139. Epub 2015 Aug 25. Review.

7.

Consequences of periodic α-to-β(3) residue replacement for immunological recognition of peptide epitopes.

Cheloha RW, Sullivan JA, Wang T, Sand JM, Sidney J, Sette A, Cook ME, Suresh M, Gellman SH.

ACS Chem Biol. 2015 Mar 20;10(3):844-54. doi: 10.1021/cb500888q. Epub 2015 Jan 5.

8.

Backbone modification of a polypeptide drug alters duration of action in vivo.

Cheloha RW, Maeda A, Dean T, Gardella TJ, Gellman SH.

Nat Biotechnol. 2014 Jul;32(7):653-5. doi: 10.1038/nbt.2920. Epub 2014 Jun 15.

9.

A new dehydrogenase from Clostridium acetobutylicum for asymmetric synthesis: dynamic reductive kinetic resolution entry into the Taxotère side chain.

Applegate GA, Cheloha RW, Nelson DL, Berkowitz DB.

Chem Commun (Camb). 2011 Feb 28;47(8):2420-2. doi: 10.1039/c0cc04585c. Epub 2010 Dec 20.

10.

Enantioselective, ketoreductase-based entry into pharmaceutical building blocks: ethanol as tunable nicotinamide reductant.

Broussy S, Cheloha RW, Berkowitz DB.

Org Lett. 2009 Jan 15;11(2):305-8. doi: 10.1021/ol802464g.

Supplemental Content

Loading ...
Support Center